Liguang Lou

13PUBLICATIONS
28CO-AUTHORS
Molecular targetsBiomolecular modelling and designElectrochemical energy storage and conversionBiologically active moleculesGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|May 17, 2023
Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.

Wei Zhou, Peng Fang, Dongan Yu

|Mar 03, 2021
Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells.

Mi Zhang, Haitian Quan, Li Fu

|Jun 24, 2020
YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer.

Lei Wang, Quanren Wang, Piaopiao Xu

|May 03, 2020
A modular biomimetic strategy for the synthesis of macrolide P-glycoprotein inhibitors via Rh-catalyzed C-H activation.

Lu Chen, Haitian Quan, Zhongliang Xu

|Aug 26, 2019
SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met.

Mengya Tong, Mingzhao Gao, Yongping Xu

|Jul 31, 2019
Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants.

Mingzhao Gao, Hongmei Zhu, Li Fu

Pageof 3

Frequent Collaborators

1 joint publications

Haitian Quan

1 joint publications

Weibo Yang

1 joint publications

Wei Zhou

1 joint publications

Peng Fang